The FDA has taken a significant step in the fight against obesity with the approval of Foundayo, a new oral medication developed by Eli Lilly. This once-daily pill adds to the growing arsenal of GLP-1 medications designed to assist individuals in managing their weight effectively. Eli Lilly, a key player in the pharmaceutical industry, is also known for its successful injectable weight-loss treatment, Zepbound.
Understanding GLP-1 Medications
Foundayo belongs to a class of drugs known as GLP-1 receptor agonists, which also includes popular treatments like Ozempic and Wegovy. These medications function by mimicking a hormone that plays a crucial role in regulating blood glucose levels, curbing appetite, and delaying gastric emptying, thereby promoting a prolonged sense of fullness.
This latest approval marks Foundayo as the second oral GLP-1 medication available for weight management, following Novo Nordisk’s Wegovy pill, which gained FDA approval a few months earlier. While the Wegovy pill requires consumption on an empty stomach, Foundayo offers greater flexibility, allowing users to take it at any time without dietary restrictions.
The Shift Towards Oral Medications
With the rising demand for injectable GLP-1 medications, pharmaceutical companies are increasingly focused on developing oral alternatives. These pills offer a less intimidating option for patients who may be reluctant to use injections. Ken Custer, Eli Lilly’s executive vice president, emphasizes that for many individuals, the choice of a pill may signify a less severe condition, making the journey toward weight management more approachable.
Additionally, oral medications present manufacturing advantages over injectables, potentially leading to improved accessibility for patients. The previous shortage of GLP-1 injectables due to high demand highlighted the need for alternatives that can be produced more efficiently.
Clinical Efficacy of Foundayo
Clinical trials of Foundayo have demonstrated promising results. Participants who took the highest dosage over an 18-month period experienced an average weight loss of 27 pounds, translating to a 12.4 percent reduction in body weight. In contrast, those on a placebo lost only 2 pounds during the same timeframe. Eli Lilly’s existing injectable medications like tirzepatide have shown even more significant weight loss results, exceeding 20 percent.
While findings from Novo Nordisk’s Wegovy pill indicate an average weight loss of 13.6 percent over 16 months, direct comparisons between Foundayo and Wegovy are still pending as no head-to-head trials have been conducted.
Transitioning from Injectables to Pills
Eli Lilly has also explored the impact of switching from injectable GLP-1 drugs to Foundayo. Their research revealed that individuals could maintain much of their weight loss when transitioning to the oral form. Participants who switched from Wegovy to Foundayo regained an average of just 2 pounds, while those who moved from Zepbound to Foundayo saw an average gain of 11 pounds.
The active compound in Foundayo, orforglipron, is not only targeted for weight management but is also being investigated for its potential to treat various conditions, including type 2 diabetes, obstructive sleep apnea, and osteoarthritis knee pain. This broad applicability underscores the drug’s significance in the evolving landscape of metabolic health.
Accessibility and Availability
Foundayo is slated for distribution through Eli Lilly’s direct-to-consumer platform, LillyDirect, with shipping set to commence on April 6. The company plans to expand availability through retail pharmacies and telehealth providers shortly thereafter. Notably, Foundayo is also part of a collaboration with the TrumpRx platform, set to launch in November 2025.
The expedited approval process for Foundayo, completed in just 50 days, reflects an initiative by the FDA to streamline the review of medications that align with national health priorities. Typically, new drug approvals can take between six to ten months, making this rapid turnaround noteworthy.
Takeaways
- Foundayo is Eli Lilly’s new oral GLP-1 medication for weight loss, approved by the FDA.
- The pill can be taken at any time without food or water restrictions, offering greater convenience compared to its competitors.
-
Clinical trials indicate that those using Foundayo experience significant weight loss compared to placebo users.
-
The transition from injectable GLP-1 medications to Foundayo appears to help maintain weight loss for many users.
-
Foundayo will be available through LillyDirect and other retail channels, enhancing patient accessibility.
In conclusion, the approval of Foundayo represents a pivotal moment in obesity treatment, providing a versatile and user-friendly option for individuals seeking to manage their weight. With ongoing research into its broader therapeutic potential, Foundayo could play a transformative role in addressing multiple health challenges. The future of weight management is indeed looking promising with the introduction of this innovative medication.
Read more → www.wired.com